Ivabradine Could Not Decrease Mitral Regurgitation Triggered Atrial Fibrosis and Fibrillation Compared with Carvedilol
ESC Heart Failure · 2024
DOI: 10.1002/ehf2.14577 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift ESC Heart Failure, 2024. Verfasst von Wei-Chieh Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Mitral Valve Insufficiency, Heart Failure, Atrial Fibrillation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Science and Technology Council, Chi-Mei Medical Center, National Health Research Institutes.
Abstract (Originalsprache)
Background
Ivabradine, a medical treatment for heart failure (HF), reduces heart rate (HR) and prolongs diastolic perfusion time. It is frequently prescribed to patients with HF who have a suboptimal response or intolerance to beta-blockers. Degenerative mitral regurgitation (MR) is a valvular heart disease often associated with the development of HF and atrial fibrillation (AF). However, studies comparing the effects of ivabradine and beta-blockers on MR are lacking. Therefore, this study aimed to explore the potential therapeutic effects of ivabradine and carvedilol on MR using a rat model. Methods and results Using a novel echo-guided mini-invasive surgery, MR was created in 12-weeks-old Sprague–Dawley rats. After 2 weeks, the rats were randomized to receive either ivabradine or carvedilol for 4 weeks. Echocardiography was performed at baseline and at two-week intervals. Following haemodynamic studies, postmortem tissues were analysed. Notably, the MR-induced myocardial dysfunction did not improve considerably after treatment with ivabradine or carvedilol. However, in haemodynamic studies, pharmacological therapies, particularly carvedilol, mitigated MR-induced chamber dilatation (end-systolic volume and end-diastolic volume; MR vs. MR + Carvedilol; P < 0.05) and decreased compliance (end-systolic pressure–volume relationship; MR vs. MR + Carvedilol; P < 0.05). Compared with ivabradine, a shorter duration (MR vs. MR + Carvedilol; P < 0.05) and reduced inducibility (MR vs. MR + Carvedilol and MR vs. MR + Ivabradine; P < 0.05) of AF were observed in MR rats treated with carvedilol. Similarly, reduced cardiac fibrosis and apoptosis were observed in the MR rat model in the treatment groups, especially in those treated with carvedilol (MR vs. MR + Carvedilol; P < 0.01).
Conclusions
Although both ivabradine and carvedilol, at least in part, mitigated MR-induced chamber dilatation and decreased compliance, carvedilol had a better effect on reversing MR-induced cardiac fibrosis, apoptosis, and arrhythmogenesis than ivabradine. When compared with Ivabradine, MR rats treated with carvedilol exhibited a shorter duration and reduced inducibility of AF, thus providing more effective suppression of HCN4. Further investigations are required to validate our findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan.
- Department of Internal Medicine, Division of Cardiology, Chi Mei Medical Center, Tainan, Taiwan.
- College of Medicine, Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Surgery, Division of Cardiovascular Surgery, Chi Mei Medical Center, Tainan, Taiwan.
- Department of Hospital and Health Care Administration, Chia Nan University of Pharmacy and Science, Tainan, Taiwan.
- School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Kaohsiung, Taiwa…
ORCID-Profile: Wei-Chieh Lee
Förderung
- National Science and Technology Council
- Chi-Mei Medical Center
- National Health Research Institutes
- Chi Mei Medical Center
Zitieren
APA
Lee, W. C., Lin, Y. W., Shih, J. Y., Chen, Z. C., Wu, N. C., & Chang, W. T. (2024). Ivabradine Could Not Decrease Mitral Regurgitation Triggered Atrial Fibrosis and Fibrillation Compared with Carvedilol. ESC Heart Failure. https://doi.org/10.1002/ehf2.14577
Vancouver
Lee WC, Lin YW, Shih JY, Chen ZC, Wu NC, Chang WT. Ivabradine Could Not Decrease Mitral Regurgitation Triggered Atrial Fibrosis and Fibrillation Compared with Carvedilol. ESC Heart Failure. 2024. doi:10.1002/ehf2.14577
BibTeX
@article{Lee2024,
author = {Lee, Wei-Chieh and Lin, Yu-Wen and Shih, Jhih-Yuan and Chen, Zhih-Cherng and Wu, Nan-Chun and Chang, Wei-Ting},
title = {Ivabradine Could Not Decrease Mitral Regurgitation Triggered Atrial Fibrosis and Fibrillation Compared with Carvedilol},
journal = {ESC Heart Failure},
year = {2024},
doi = {10.1002/ehf2.14577}
}
EUVIMED